1Landman J,Chang Y,Kavaler E,et al.Sensitivity and specificity of NMP-22,telomerase,and BTA in the detection of human bladder cancer.Urology,1998,52:398-402.
2Miyaaga N,Akaza H,Ishikawa S,et al.Clinical evaluation of nuclear matrix protein-22 (NMP-22) in urine as a novel marker for urothelial cancer.Eur Urol,1997,31:163-168.
3Sarosdy MF,Devere White RW,Soloway MS,et al.Results of a multicentre trial using the BTA test to monitor for and diagnose recurrent bladder cancer.J Urol,1995,54:379-383.
4Ellis WJ,Blumstein BA,Ishak LM,et al.Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors.Multicentre study group.Urology,1997,50:882-887.
5Pariente JL,Bordenavel,Jacob F,et al.Analytical and prospective evaluation of urinary cytokeratin 19 fragment in bladder cancer.J Urol,2000,164:1922-1925.
7Schmetter BS,Habicht KK,Lamm DL,et al.A multicentre trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer.J Urol,1997,158:801-805.
8Sugiyama M,Woodman A,Sugion T,et al.Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine.J Clin Pathol Mol Pathol,1995,48:142.
9Lokeshwer VB,Obek C,Pham HT,et al.Urinary hyaluronic acid and hyaluronidase:markers for monitoring bladder cancer detection and evaluation of grade.J Urol,2000,163:348-356.
10Eissa S,Kassim S,EI-Ahmady O.Detection of bladder tumors:role of cytology,morphtology-based assays,biochemical and molecular markers.Curr Opin Obstet Gynecol,2003,15:395-403.
二级参考文献10
1Grossman D,McNiff JM,Li F,et al.Expression of the apoptosis inhibitor,survivin,in nonmelanoma skin cancer and gene targeting in a keratinocyte cell.Lab Invest,1999,79:1121-1126.
2Takamizawa S,Scott D,Wen J,et al.The survivin:fas ratio in pediatric renal tumors.J Pediatr Surg,2001,36 :37-42.
3Smith SD,Wheeler MA,Plescia J,et al.Urine detection of survivin and diagnosis of bladder cancer.JAMA ,2001,285:324-328.
4Ambrosini G,Adida C,Altieri DC,et al.A novel anti-apoptosis gene,survivin,expressed in cancer and lymphoma.Nat Med,1997,3:917-921.
5Li F,Ambrosini G,Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by survivin.Nature,1998,396:580-584.
6Mesri M,Morales-Ruiz M,Ackermann EJ,et al.Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting.Am J Patho1,2001,158 :1757-1765.
7Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95),Bax,caspase,and anticancer drugs.Cancer Res,1998,58:5315-5320.
8Swana HS,Grossman D,Anthony JN,et al.Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer.N Engl J Med,1999,341:452-453.
9Mao L, Schoenberg MP, Scicchitano M, et al. Molecular detection of primary bladder cancer by microsatellite analysis. Science, 1996,271:659-662.
10Gonzalez ZM, Ruppert JM,Tokino K,et al. Microsatellite instability in bladder cancer. Cancer Res, 1994,53:5620-5623.
6Benjamin N , Vivian B , Amos S, et al. Evaluation of Urine CYFRA21-1 for the Detection of Primary and Recurrent Bladder Carcinoma[ J]. Cancer,2004,94:2912-2914.
7Barak V , Goike H , Katja W, et al. Clinical utility of cytokeratins as tumor markers [ J ]. Clinical Biochemistry , 2004,37:529- 540.
8Almdy O, Halim AG, Din AG, et al. The clinical value of CYFRA21-1 in bladder caner patients [ J]. Anti cancer Res, 1999,19 : 2603-2609.
9Senga Y, Kimura G, Hattori T, et al. Clinical evaluation of soluble cytokeratin 19 fragment inserum and urine of the patients inbladder cancer [ J]. J Urol,1995,153:913-918.
10Kitsukawa SI , Ohyashiki K, Yahata N ,et al. Comparison of screening methods in the detection of bladder cancer [ J ]. J Urol, 1999,161:388-394.
